Dose Escalated Radiotherapy Combined With Androgen Deprivation Improves Outcomes in High Risk Prostate Cancer
Higher radiation doses may improve long-term outcomes for prostate cancer
A Phase 3 trial demonstrates that 80 Gy of radiotherapy plus long-term ADT significantly improves 10-year progression-free survival.
A large trial shows that a higher dose of radiation combined with hormone therapy may help men with high-risk prostate cancer stay cancer-fr…
Trial protocol evaluates 9-month ADT plus ARTA for high-risk prostate cancer non-inferiority
New trial tests shorter hormone therapy for high-risk prostate cancer
This Phase II trial protocol evaluates 9 months of androgen deprivation therapy (ADT) plus 6 months of an androgen receptor-targeted agent (…
A new clinical trial is testing if a shorter, more intense hormone treatment can work just as well as standard care for high-risk prostate c…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
New Treatment Options for Men with Advanced Prostate Cancer
This Phase 3 randomized controlled trial of 1144 patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate …
A large study shows that adding a specific radioactive treatment to standard hormone therapy can help slow cancer growth.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Salvage radiotherapy combined with androgen deprivation therapy improves biochemical progression-free survival in prostate cancer
Combined Therapy Shows Better Outcomes for Prostate Cancer Patients
This systematic review and meta-analysis of men with biochemical recurrence after radical prostatectomy found that combining salvage radioth…
Combining salvage radiotherapy with hormone therapy may improve disease control and reduce the risk of spreading in certain types of prostat…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Phase II trial of CyberKnife SBRT and androgen deprivation therapy in unfavorable intermediate- to high-risk localized prostate cancer
Small trial shows CyberKnife radiation plus hormone therapy is well tolerated for high-risk prostate cancer
This Phase II trial evaluated CyberKnife-based SBRT with simultaneous integrated boost and androgen deprivation therapy in 20 patients with …
A small study of 20 men with high-risk prostate cancer found that CyberKnife radiation plus hormone therapy was well tolerated with low rate…
MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
Early MRI scans shrink after treatment to help spot prostate cancer recurrence sooner
This prospective phase II trial protocol reports early results from 97 men with unfavorable-intermediate-risk or high-risk localized prostat…
New MRI scans taken before and during treatment for prostate cancer show clear shrinkage that could help doctors target the tumor more accur…
All androgen deprivation therapy Articles
- Trial protocol evaluates 9-month ADT plus ARTA for high-risk prostate cancer non-inferiority
- Dose Escalated Radiotherapy Combined With Androgen Deprivation Improves Outcomes in High Risk Prostate Cancer
- Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
- Lu-PSMA-617 combined with ADT and ARPI reduced radiographic progression risk by 28%
- Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
- Salvage radiotherapy combined with androgen deprivation therapy improves biochemical progression-free survival in prostate cancer
- Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
- Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
- Time to biochemical progression predicts second events in high-risk prostate cancer
- Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
- Phase II trial of CyberKnife SBRT and androgen deprivation therapy in unfavorable intermediate- to high-risk localized prostate cancer
- MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
- Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
- Expert panel agrees on early detection and ARPI/ADT role for high-risk prostate cancer BCR